Form 4: Kura Oncology CEO Granted Stock Options

Troy Edward Wilson, President and CEO of Kura Oncology, Inc., was granted options to purchase 625,000 shares of common stock on January 2, 2025.

Summary

• Troy Edward Wilson, the President and CEO of Kura Oncology, Inc., was granted an option to purchase 625,000 shares of the company's common stock on January 2, 2025.
• The exercise price of the option is $8.68 per share.
• The option vests in 48 equal monthly installments starting on the grant date and expires on January 1, 2035.
• Following the transaction, Wilson directly owns options for 625,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management incentives with shareholder value.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with those of shareholders. This grant is typical for CEOs of publicly traded companies.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The size of the grant (625,000 shares) and the vesting schedule (48 months) are within typical ranges for companies of Kura Oncology's size and stage of development.
• Comparing to similar companies like Mirati Therapeutics or Relay Therapeutics, executive compensation packages often include a mix of salary, stock options, and performance-based bonuses.

Stakeholder Impact

• Shareholders: The grant of stock options can be seen as a positive sign, aligning the CEO's interests with increasing shareholder value.
• Employees: The grant could boost employee morale by demonstrating confidence in the company's future.

Key Dates